ETBX-021

AXP000155.1 · Cancer vaccine

Platform
adenovirus (Ad5 [E1-, E2b-])
Targets
ERBB2
Originator
Etubics
Sponsor
ImmunityBio

Names

NameTypeSource
ETBX-021preferred name, codecurator, ncit
Ad5 [E1-, E2b-]-HER2/neu Vaccine ambiguoussynonymncit
Adenovirus Type 5 E1/E2b-deleted HER2/neu Vaccine ETBX-021 ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 [E1-, E2b-]
Replication
non replicating
Modifications
E1 and E2b regions deleted (replication-defective, reduced late gene expression)
Transgenes
HER2/neu
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C150517
FDA UNII
S4MK9TOL0D

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03563157QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/22018-09-282019-04-212Colorectal Cancer Metastatic; mCRC
NCT03563144QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 22018-082019-12-300Metastatic Pancreatic Cancer
NCT03169777QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/22018-082019-010Colorectal Cancer
NCT03586869QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/22018-07-172019-04-173Pancreatic Cancer
NCT03169738QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/22018-022019-010Non-small Cell Lung Cancer
NCT03387111QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/22018-01-092019-04-174Squamous Cell Carcinoma
NCT03197584QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/22017-122019-020Ovarian Cancer
NCT03197571QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Urothelial Carcinoma
NCT03169764QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/22017-122019-010Head and Neck Squamous Cell Carcinoma
NCT02751528QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast CancerTerminatedPhase 12017-03-042018-08-163Cancer

Recent changes

No changes recorded in its trials yet.

Notes

Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Ad5 [E1-, E2b-]-HER2/neu Vaccine.

How to cite

ETBX-021 (AXP000155.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000155.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.